Fig. 1.
Fig. 1. Treatment of FGFR3-transduced cells with melphalan, doxorubicin, and dexamethasone. / (A) B9MINV, B9-WT, and B9-TD cells were induced with various concentrations of drug and analyzed using an MTT assay kit 72 hours after induction. Elevated expression of FGFR3 confers resistance to dexamethasone. (B) Ethidium bromide/acridine orange–stained (green represents viable cells) B9MINV and B9-TD cells either untreated or treated with 10 μM Dex and rescued with IL-6. Only B9MINV cells are sensitive to dexamethasone treatment.

Treatment of FGFR3-transduced cells with melphalan, doxorubicin, and dexamethasone.

(A) B9MINV, B9-WT, and B9-TD cells were induced with various concentrations of drug and analyzed using an MTT assay kit 72 hours after induction. Elevated expression of FGFR3 confers resistance to dexamethasone. (B) Ethidium bromide/acridine orange–stained (green represents viable cells) B9MINV and B9-TD cells either untreated or treated with 10 μM Dex and rescued with IL-6. Only B9MINV cells are sensitive to dexamethasone treatment.

Close Modal

or Create an Account

Close Modal
Close Modal